Stone Run Capital LLC decreased its stake in Thermo Fisher Scientific Inc (NYSE:TMO) by 0.4% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 24,120 shares of the medical research company’s stock after selling 100 shares during the period. Thermo Fisher Scientific accounts for about 2.2% of Stone Run Capital LLC’s investment portfolio, making the stock its 18th largest position. Stone Run Capital LLC’s holdings in Thermo Fisher Scientific were worth $3,705,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of TMO. Gulf International Bank UK Ltd raised its stake in shares of Thermo Fisher Scientific by 2.1% in the first quarter. Gulf International Bank UK Ltd now owns 122,961 shares of the medical research company’s stock valued at $18,886,000 after buying an additional 2,500 shares during the last quarter. Quadrant Capital Group LLC raised its stake in shares of Thermo Fisher Scientific by 3.7% in the first quarter. Quadrant Capital Group LLC now owns 2,913 shares of the medical research company’s stock valued at $439,000 after buying an additional 104 shares during the last quarter. Newman Dignan & Sheerar Inc. raised its stake in shares of Thermo Fisher Scientific by 2.2% in the first quarter. Newman Dignan & Sheerar Inc. now owns 3,688 shares of the medical research company’s stock valued at $566,000 after buying an additional 80 shares during the last quarter. Country Club Trust Company n.a. raised its stake in shares of Thermo Fisher Scientific by 4.9% in the first quarter. Country Club Trust Company n.a. now owns 40,390 shares of the medical research company’s stock valued at $6,204,000 after buying an additional 1,894 shares during the last quarter. Finally, National Pension Service raised its stake in shares of Thermo Fisher Scientific by 1.3% in the first quarter. National Pension Service now owns 282,001 shares of the medical research company’s stock valued at $43,403,000 after buying an additional 3,599 shares during the last quarter. Institutional investors own 87.15% of the company’s stock.

Shares of Thermo Fisher Scientific Inc (NYSE TMO) traded down 0.68% on Thursday, reaching $172.09. 271,643 shares of the company’s stock traded hands. Thermo Fisher Scientific Inc has a 52-week low of $139.07 and a 52-week high of $182.87. The stock has a market cap of $67.14 billion, a price-to-earnings ratio of 29.98 and a beta of 1.06. The firm’s 50-day moving average is $176.96 and its 200-day moving average is $165.20.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, July 26th. The medical research company reported $2.30 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.27 by $0.03. Thermo Fisher Scientific had a net margin of 11.80% and a return on equity of 15.97%. The firm had revenue of $5 billion during the quarter, compared to analyst estimates of $4.92 billion. During the same quarter in the prior year, the business earned $2.03 earnings per share. Thermo Fisher Scientific’s revenue for the quarter was up 10.2% on a year-over-year basis. Analysts anticipate that Thermo Fisher Scientific Inc will post $9.24 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Monday, October 16th. Investors of record on Friday, September 15th will be given a dividend of $0.15 per share. The ex-dividend date of this dividend is Thursday, September 14th. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.35%. Thermo Fisher Scientific’s dividend payout ratio is 10.45%.

ILLEGAL ACTIVITY WARNING: This piece was first published by Daily Political and is the property of of Daily Political. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The correct version of this piece can be accessed at https://www.dailypolitical.com/2017/08/10/thermo-fisher-scientific-inc-tmo-shares-sold-by-stone-run-capital-llc.html.

Several equities research analysts have recently issued reports on TMO shares. Leerink Swann set a $187.00 price target on shares of Thermo Fisher Scientific and gave the stock a “buy” rating in a research note on Thursday, April 27th. Barclays PLC set a $175.00 price target on shares of Thermo Fisher Scientific and gave the stock a “buy” rating in a research note on Wednesday, April 26th. BTIG Research raised their price target on shares of Thermo Fisher Scientific from $180.00 to $190.00 and gave the stock a “buy” rating in a research note on Friday, April 28th. Deutsche Bank AG raised their price objective on shares of Thermo Fisher Scientific from $163.00 to $188.00 and gave the stock a “buy” rating in a report on Friday, April 28th. Finally, Jefferies Group LLC raised their price objective on shares of Thermo Fisher Scientific from $160.00 to $175.00 and gave the stock a “hold” rating in a report on Friday, April 28th. One research analyst has rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company. Thermo Fisher Scientific currently has an average rating of “Buy” and an average target price of $188.56.

In related news, CEO Marc N. Casper sold 20,000 shares of the company’s stock in a transaction on Thursday, June 1st. The shares were sold at an average price of $172.79, for a total transaction of $3,455,800.00. Following the completion of the transaction, the chief executive officer now owns 269,279 shares in the company, valued at $46,528,718.41. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Daniel P. Shine sold 4,688 shares of the company’s stock in a transaction on Wednesday, May 24th. The stock was sold at an average price of $171.88, for a total transaction of $805,773.44. Following the transaction, the insider now owns 29,200 shares of the company’s stock, valued at approximately $5,018,896. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 27,188 shares of company stock valued at $4,702,223. 0.49% of the stock is owned by company insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.